New combo shows promise for tough head and neck cancers
NCT ID NCT04831320
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study tested a combination of two drugs—nab-paclitaxel (a chemotherapy) and nivolumab (an immunotherapy)—in 46 people with advanced head and neck cancer that had stopped responding to a prior immunotherapy. The goal was to see if the combo could shrink tumors or slow the cancer's growth better than historical results. Participants received the drugs intravenously, and the study measured how many had a significant tumor reduction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Leftover immunotherapy may boost chemo: new study investigates timing
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- Remote hearing tests could save cancer Patients' hearing
- New drug cocktail aims to extend life in Tough-to-Treat head and neck cancer
- New combo therapy shows promise for Hard-to-Treat head and neck cancer
- Blood pressure drug joins forces with immunotherapy and radiation to fight head and neck cancer